![](/img/cover-not-exists.png)
PCN264 QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE PROGRESSION OR TOXICITY (Q-TWIST) OF NIVOLUMAB PLUS IPILIMUMAB (NIVO+IPI) VS SUNITINIB (SUN) AMONG UNTREATED ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS (PATIENTS) WITH INTERMEDIATE OR POOR PROGNOSTIC RISK
Shah, R., Botteman, M., Kwon, Y., Gooden, K.M., Cella, D., Motzer, R.Volume:
22
Language:
english
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.04.385
Date:
May, 2019
File:
PDF, 320 KB
english, 2019